Top Markets
#1 OVERTAKE OVERTAKE +225.59%
#2 Clearpool Clearpool +34.49%
#3 Rei Rei +32.33%
#4 Arcblock Arcblock +31.36%
#5 PulseChain PulseChain +30.33%
#6 Playnance Playnance +28.09%
#7 B3 (Base) B3 (Base) +25.04%
#8 龙虾 (Lobster) 龙虾 (Lobster) +22.45%
#9 Meteora Meteora +21.02%
#10 PondCoin PondCoin +19.24%
Coin of the day
OVERTAKE OVERTAKE
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Kedudukan dalam Saham #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Harga Saham
$62.26
Disegerakkan terakhir: 2026-09-22
Modal Pasaran
$127.18B
Perubahan (1 hari)
-0.78%
Perubahan (1 tahun)
38.63%
Negara
US
Perdagangan Bristol-Myers Squibb Company (BMY)

Kategori

Healthcare
Nisbah P/E bagi Bristol-Myers Squibb Company (BMY)
Nisbah P/E pada September 2026 TTM: 14.12
Menurut laporan kewangan dan harga saham terkini Bristol-Myers Squibb Company, nisbah P/E semasa (TTM) ialah 14.12. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -12.81.
Sejarah nisbah P/E bagi Bristol-Myers Squibb Company dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 14.12 -9.55%
2025 15.61 -221.83%
2024 -12.81 -196.85%
2023 13.23 -45.39%
2022 24.22 22.34%
2021 19.80 -227.16%
2020 -15.57 -148.93%
2019 31.82 84.46%
2018 17.25 -82.77%
2017 100.10 356.89%
2016 21.91 -70.10%
2015 73.27 50.12%
2014 48.81 43.17%
2013 34.09 22.78%
2012 27.77 71.92%
2011 16.15 10.46%
2010 14.62 211.33%
2009 4.70 -46.38%
2008 8.76 -63.70%
2007 24.13 -25.86%
2006 32.55 117.67%
2005 14.95 -28.23%
2004 20.84 16.81%
2003 17.84 -17.56%
2002 21.64 5.71%
2001 20.47 -30.30%
2000 29.36 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 38.12 169.96%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 30.79 118.07%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 73.73 422.20%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 22.25 57.58%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 114.95 714.17%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.